ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
about
ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@en
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@nl
type
label
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@en
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@nl
prefLabel
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@en
ARMS2 A69S polymorphism is ass ...... n during 4 years of follow-up.
@nl
P2093
P2860
P50
P1476
ARMS2 A69S polymorphism is ass ...... en during 4 years of follow-up
@en
P2093
Alicia Megías-Fresno
Juan Donate-López
Maria Luisa Maestro-de-Las-Casas
P2860
P2888
P304
P356
10.1007/S00417-017-3748-0
P577
2017-07-25T00:00:00Z